In this event, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures will outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector.
The showcase includes a panel discussion looking at the use of new drug discovery and development technology, concepts and tools in neuroscience, as well what the future looks like for neuroscience therapies.
The showcase also includes presentations from Dr Sheldon Preskorn, SVP of Neuroscience at Dr Vince Clinical Research, Dr Kiri Granger, CSO of Monument Therapeutics and Andrew LaCroix, Lead Scientist at AxoSim. Dr Preskorn’s presentation highlights the accelerating evolution of psychiatric treatment development from one dependent on chance observations to more sophisticated and less risky molecular biology approaches. Dr Granger’s presentation covers the company’s use of precision medicine to develop effective treatment options for areas of high unmet need in psychiatry and neurology. Andrew LaCroix's presentation talks about how AxoSim predicts clinical neurotoxicity using functional cortical organoids.
The showcase will also feature product presentations from sponsors that give the audience the opportunity to learn about the latest technologies driving neuroscience drug discovery and development.
What you will learn:
Where is the opportunity in the neuroscience market?
How to uncover the best research tools to boost the development of new treatments
How to recognise and tackle barriers in neuroscience research
What are the technologies that can help create efficiencies and get to market faster?
What does the future hold for neuroscience?
A Q&A session with the speakers follows each presentation.
